Debate Sobre los IPT en Oncología

We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.

This event is organized in partnership with Bamberg Health, a unique event company helping the pharma and healthcare industries move forward, and will be held in Spanish language.

What we will cover

Pricing & reimbursement (P&R) decisions for new drugs in Spain are based on the criteria set in the Law on Guarantees and Rational Use of Medicinal Products (LGURM) (RD 1/2015), and the clinical evidence, economic value, and positioning of each new drug in relation to the Therapeutic Positioning Report (TPR). Despite this clear framework, the weight of each criterion on P&R decisions is not transparent.

For oncology therapies in particular, timeline of the P&R decision is critical, however, the gap between the approval of new medicines by EMA and their reimbursement in Spain can be noticeable. As of January 2022, more than 100 TPRs had a delay of 400 days. Both clinicians and patients regret these delays in access and want to streamline evaluation processes with new TPRs.

During this event we will discuss the findings of our recent study “Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain” as a starting point and will seek solutions that favor a structured, agile, transparent and predictable P&R decisions in the future.

Who should attend

• Pharmacists
• Clinical oncologists
• Representatives of the AEMPS, the Ministry, the Autonomous Communities
• Representatives of scientific societies
• Patients